CD4 and cancer: The neoantigen vaccination derived from RNA-seq and whole-exome sequencing datasets that were currently of interest to major pharmaceutical companies, the neoantigens recognized by CD4 T cell and MHC class II-restricted manner played a vital role in the recovery of cancer patients (60, 61).